Alex Goldberg

Opexa Therapeutics, Inc. (NASDAQ:OPXA) and SanDisk Corp. (NASDAQ:SNDK) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/19/2013 -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Opexa Therapeutics, Inc. (NASDAQ:OPXA) and SanDisk Corp. (NASDAQ:SNDK).

Opexa Therapeutics, Inc. (NASDAQ:OPXA) a biopharmaceutical company that develops personalized cellular therapies to treat multiple sclerosis based on its proprietary T-cell technology is currently down (-10.64%) on 3,255,595 shares traded after Opexa Therapeutics priced 4.12 mln shares of common stock at $1.70. Opexa Therapeutics, Inc. (NASDAQ:OPXA) is currently down (-67.82%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Opexa Therapeutics, Inc. (NASDAQ:OPXA)

SanDisk Corp. (NASDAQ:SNDK) a company that designs, develops, manufactures, and markets flash storage card products that are used in various consumer electronics products is currently up (+0.73%) on 2,563,861 shares traded after SanDisk was Named Thomson Reuters Top 100 Global Innovator for Third Consecutive Year. SanDisk Corp. (NASDAQ:SNDK) is currently up (+62.77%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about SanDisk Corp. (NASDAQ:SNDK)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com